SARS-CoV-2 created in 2003 patent US-2006257852-A1 assigned to CHIRON CORP (US) which was acquired by Novartis (Switzerland manufacturer of generic drug hydroxychloroquine)

US Patent and Trademark Office

SARS-CoV-2 is very similar to SARS. What is different is what makes it a novel SARS coronavirus (SARS-CoV). What’s different is a protein that is exclusively found in SARS-CoV-2 genome and not in SARS-CoV. SARS-CoV-2 genome contains the protein ORF10.

“In a recent study comparison of the proteins encoded by SARS-CoV-2 with the proteins of SARS-CoV revealed the presence of novel ORF8 and ORF10 proteins in SARS-CoV-2. …. ORF10 is the only protein that is not present in other human coronaviruses” Genes of SARS-CoV-2 and emerging variants 

A 2003 Patent US-2006257852-A1 assigned to CHIRON CORP (US), which was acquired by Novartis (Switzerland) on April 20, 2006 informs us when and how SARS-CoV-2 was created in a lab. Patent US-2006257852-A1 specifically names the ORF10 protein – a protein that is exclusively found in SARS-CoV-2 genome and not in SARS-CoV, being used/encoded in the fusion protein of the patented novel SARS coronavirus:

The invention relates to nucleic acids and proteins from the SARS coronavirus. These nucleic acids and proteins can be used in the preparation and manufacture of vaccine formulations, diagnostic reagents, kits, etc.

Accordingly, the invention further includes a SARS virus subunit vaccine comprising a fusion protein. Preferably, the fusion protein comprises a first amino acid sequence encoded by a SARS virus polynucleotide sequence. SARS virus polynucleotide sequences which may encode said first amino acid sequence include one or more of the SARS virus polynucleotide sequences identified in this application and fragments thereof. 

The fusion protein may comprise an amino acid sequence of a SARS virus protein or a fragment thereof. Said SARS virus protein may be selected from one or more of the group consisting of the following SARS virus proteins: P28, P65, Nsp1, Nsp2 (3CL protease), Nsp3, Nsp3, Nsp4, Nsp 5, Nsp6, Nsp 7, Nsp 8, Nsp 9 (RNA polymerase), Nsp 10 (helicase), Nsp 11, Nsp 12, Nsp 13, Spike, Orf 3, Orf 4, Envelope, Matrix, Orf7, Orf8, Orf9, Orf10, Orf11, Nucleocapsid and Orf13. 

In one embodiment, the fusion protein comprises a first amino acid sequence comprising a SARS virus antigen or a fragment thereof. Said SARS virus amino acid sequence may comprise one or more of the T-epitope sequences identified above.

Patent US-2006257852-A1

uniqueness of ORF10 and predicted intrinsic characteristics support possible involvement of ORF10 protein in giving COVID-19 its specific characteristics like spread and virulence” WHO

ORF8, “although non-essential and the precise functions are unknown, it has been suggested that this protein assists in SARS-CoV-2 replication in the early secretory pathway and in immune evasion. … Since ORF8 is not an essential protein for the SARS-CoV-2 life cycle, ORF8 is likely to functionally associate with other SARS-CoV-2 components to assist with SARS-CoV-2 replication and assembly in host cells, but, the coordinated process of this mechanism is still unknown”

“It is also noteworthy that ORF10, exclusively found in SARS-CoV-2 (and not in SARS-CoV), has been shown to interact with the Cullin 2 (CUL2) RING E3 ligase complex, possibly hijacking its function. It is not known what the implications of this interaction is for virus replication, but a similar complex is recruited by other viral proteins, including HIV Vif, Adenovirus E4Orf6, EBV Bzlf and others (Mahon et al., 2014). In all cases, the virus exploits this to target an antiviral protein for proteasome degradation, and it is therefore likely the case also for Orf10.” Structural Characterization of SARS-CoV-2: Where We Are, and Where We Need to Be

noteworthy that Orf10, exclusively found in SARS-CoV-2 (and not in SARS-CoV)

Novartis novel SARS virus subunit vaccine link to COVID-19 outbreak in Wuhan China

In 2006, Novartis acquired the California-based Chiron Corporation. Chiron had been divided into three units: Chiron Vaccines, Chiron Blood Testing, and Chiron BioPharmaceuticals. The biopharmaceutical unit was integrated into Novartis Pharmaceuticals, while the vaccines and blood testing units were made into a new Novartis Vaccines and Diagnostics division. Also in 2006, Sandoz, a Novartis division, became the first company to have a biosimilar drug approved in Europe with its recombinant human growth hormone drug.

In 2009, Novartis reached an agreement to acquire an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the group’s limited presence in this fast-growing market segment. This proposed acquisition required government and regulatory approvals in China.

On March 22, 2011 Novartis announced that it completed the transaction to acquire a 85 percent (majority) stake in China’s Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd “This agreement combines the strength of our vaccines R&D strategy and pipeline with Tianyuan’s deep knowledge of the vaccines market in China, enabling us to better deliver a broad range of vaccines to the Chinese people,” Andrin Oswald, Head of Novartis Vaccines and Diagnostics.

Novartis acquiring majority stake in China’s Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd provides a plausible explanation for why SARS-CoV-2 originated in China. The short-lived COVID-19 epidemic (“SARS-CoV-2 epidemic in China peaked and plateaued between 23 January and 2 February 2020, and had been declining steadily since then” Tedros Adhanom Ghebreyesus, director-general of WHO) began immediately after the People’s Republic of China began mandatory SARS vaccinations in Wuhan as required by “Vaccine Administration Law of the People’s Republic of China”. Mandatory vaccination throughout China came into effect on 1 Dec 2019

“The Vaccine Administration Law of the People’s Republic of China, adopted at the 11th Meeting of the Standing Committee of the Thirteenth National People’s Congress on June 29, 2019, is hereby promulgated and shall go into effect as of December 1, 2019.” Xi Jinping
President of the People’s Republic of China June 29, 2019

Article 6 The State implements immunization program system.

All citizens who reside in the territory of the People’s Republic of China shall be entitled and obliged to be immunized with national immunization program vaccines according to law. The government shall provide immunization program vaccines for the citizens free of charge.

Novartis acquired majority stake in China’s Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd for the stated purpose of “enabling us to better deliver a broad range of vaccines to the Chinese people“. It is therefore highly plausible that Novartis patented novel “SARS virus subunit vaccine comprising a fusion protein comprising an amino acid sequence of a SARS virus protein … Said SARS virus protein may be selected from one or more of the group consisting of the following SARS virus proteins … Orf8 … Orf10“, caused the COVID-19 outbreak in Wuhan China.

Source

You can skip to the end and leave a response. Pinging is currently not allowed.

Leave a Reply

*

Powered by WordPress | Designed by: Premium WordPress Themes | Thanks to Themes Gallery, Bromoney and Wordpress Themes